Tudor Investment Corp
CRSP icon

Tudor Investment Corp’s CRISPR Therapeutics CRSP Stock Holding History

Tudor Investment Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Buy
43,411
+3,943
+10% +$208K ﹤0.01% 1829
2025
Q4 		$2.07M Buy
+39,468
New +$2.36M ﹤0.01% 1785
2025
Q2 		– Sell
-51,242
Closed -$1.98M – 3334
2025
Q1 		$1.74M Buy
51,242
+32,905
+179% +$1.39M 0.01% 1443
2024
Q4 		$722K Sell
18,337
-28,662
-61% -$1.35M ﹤0.01% 1970
2024
Q3 		$2.21M Buy
+46,999
New +$2.38M 0.01% 1140
2024
Q2 		– Sell
-21,790
Closed -$1.49M – 2388
2024
Q1 		$1.49M Buy
21,790
+5,741
+36% +$411K 0.01% 1164
2023
Q4 		$1M Buy
+16,049
New +$887K 0.01% 1437
2023
Q3 		– Sell
-25,562
Closed -$1.44M – 2371
2023
Q2 		$1.44M Buy
+25,562
New +$1.45M 0.02% 1085
2023
Q1 		– Sell
-24,949
Closed -$1.01M – 2499
2022
Q4 		$1.01M Buy
24,949
+1,056
+4% +$56K 0.02% 1094
2022
Q3 		$1.56M Buy
23,893
+4,211
+21% +$305K 0.03% 638
2022
Q2 		$1.2M Sell
19,682
-5,301
-21% -$312K 0.03% 781
2022
Q1 		$1.57M Sell
24,983
-4
-0% -$251 0.04% 671
2021
Q4 		$1.89M Buy
24,987
+3,701
+17% +$323K 0.03% 661
2021
Q3 		$2.38M Buy
+21,286
New +$2.67M 0.04% 601
2021
Q1 		– Sell
-15,841
Closed -$2.42M – 1604
2020
Q4 		$2.42M Buy
15,841
+8,858
+127% +$1.05M 0.07% 346
2020
Q3 		$584K Buy
6,983
+1,916
+38% +$170K 0.03% 755
2020
Q2 		$372K Sell
5,067
-6,182
-55% -$361K 0.02% 813
2020
Q1 		$477K Sell
11,249
-5,484
-33% -$283K 0.04% 511
2019
Q4 		$1.02M Buy
+16,733
New +$914K 0.05% 489
2018
Q2 		– Sell
-8,608
Closed -$393K – 1070
2018
Q1 		$393K Buy
+8,608
New +$355K 0.01% 649

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tudor Investment Corp's CRSP Position: Q1 2026 in Review

Tudor Investment Corp increased its CRISPR Therapeutics (CRSP) stake by 10% in Q1 2026, buying an estimated $208K and bringing the position to 43,411 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Tudor Investment Corp first reported a position in CRSP in Q1 2018 and has held it in 20 quarters since. The position peaked at $2.42M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Tudor Investment Corp held 43,411 shares of CRISPR Therapeutics worth $2.07M as of Q1 2026.
  • Tudor Investment Corp bought 3,943 CRISPR Therapeutics shares in Q1 2026, an estimated $208K.
  • CRISPR Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #1829 holding.
  • Tudor Investment Corp first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • Tudor Investment Corp's CRISPR Therapeutics position peaked at $2.42M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.